Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
For the nine months ended September 30, 2026, BNSF reported total revenues of $19.4 billion, an 11.4% increase over the prior year, driven by growth across all freight categories. Net income rose to $4.7 billion compared to $4.1 billion in 2025, despite higher fuel and compensation expenses. The company maintained a strong liquidity position with $6.7 billion in net cash provided by operating activities during the period.
Mereo BioPharma reported third quarter 2026 financial results and provided updates on its rare disease pipeline, including setrusumab for osteogenesis imperfecta and alvelestat for AATD-LD. The company ended the quarter with $26.1 million in cash, which is expected to fund operations into late-2027, excluding potential milestone payments from partners Ultragenyx and Sentynl Therapeutics.
“During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027 for Mereo, our shareholders and the patients we aim to serve.”
Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma
Spruce Biosciences reported a significant increase in cash and cash equivalents to $87.7 million as of September 30, 2026, compared to $48.9 million at year-end 2025. However, the company faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $341.7 million and a need for additional financing to develop its lead product candidate, tralesinidase alfa (TA-ERT).
Trinseo reported Q3 2026 net sales of $779 million, a 5% increase year-over-year, and an Adjusted EBITDA of $51 million. The company reported a net loss of $49 million, which included $43 million in reorganization charges related to its ongoing debt restructuring proceedings. Trinseo also announced plans to cease Latex Binders manufacturing at its Terneuzen site as part of a continuing cost optimization strategy.
Quanterix reported Q3 2026 revenue of $35.0 million, representing a 6.3% sequential increase despite market softness. The company ended the quarter with $80.7 million in cash and marketable securities while narrowing its net loss by 35.6% year-over-year to $21.6 million. Management highlighted new commercial leadership and expanded insurance coverage for its Alzheimer’s disease blood tests as key growth drivers.
Term
Q3 2026
“We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses.”
Everett Cunningham, President & CEO
“We are confident about the benefits and differentiated positioning of our research tools and diagnostics businesses, especially with new commercial leadership focused on sustained growth.”
OPAL Fuels reported Q3 2026 financial results with Adjusted EBITDA of $26.7 million, a 32% increase year-over-year driven by RNG production progress and Fuel Station Services growth. While net income improved to $1.7 million, the company noted that operational improvements took longer than expected, leading to a revised 2026 RNG production outlook modestly below previous guidance.
Term
Q3 2026
“Progress in RNG production, growth in Fuel Station Services, 45Z contributions and lower general and administration costs drove 32% Adjusted EBITDA growth compared to the third quarter last year.”
Adam Comora, Co-Chief Executive Officer
“While we are encouraged by the sequential production growth, which is continuing in the fourth quarter, the operational improvements took longer to implement. We now expect 2026 RNG production to be modestly below our guidance range.”
Uniti Group reported Q3 2026 consolidated revenue of $848.1 million and a net loss of $244.5 million, driven by record Kinetic consumer fiber construction and net adds. The company raised its full-year 2026 revenue guidance to a range of $3.665 billion to $3.695 billion, citing robust demand from hyperscalers and large enterprises for fiber infrastructure.
Term
Q3 2026
“We once again had a record-breaking quarter at Uniti on several fronts, highlighted by our highest level of Kinetic consumer fiber premises constructed in a single quarter of 162,000 households. We also saw the most Kinetic consumer fiber net adds ever on record, resulting in 50% of Kinetic’s total footprint now passed with fiber.”
Kenny Gunderman, President and Chief Executive Officer
“These robust bookings continue to be fueled by the unprecedented demand we are seeing from Hyperscalers, Superscalers, and increasingly traditional large enterprises for both dark and lit wave solutions. We remain well positioned as a premier insurgent fiber provider to capture substantial share of this generational growth.”
Kenny Gunderman, President and Chief Executive Officer
Superior Group of Companies reported net sales of $146.0 million for the third quarter of 2026, a 5.4% increase over the prior year period. Net income for the nine months ended September 30, 2026, rose to $4.6 million compared to $3.5 million in 2025, despite a $2.6 million trade name impairment charge. The company significantly improved its operating cash flow to $30.7 million for the first nine months of 2026, up from $1.3 million in the prior year.
ADC Therapeutics reported Q3 2026 net product revenue of $21 million and highlighted a strategic financial restructuring completed in October that extended its cash runway into 2029. The company also noted multiple upcoming data presentations for ZYNLONTA at the ASH 2026 annual meeting.
Term
Q3 2026
“During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics' balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA®.”
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
“The upcoming LOTIS-7 Phase 1b and marginal zone lymphoma IIT data at ASH highlights the potential for ZYNLONTA to play an important role in the treatment of r/r DLBCL and indolent lymphomas.”
Mohamed Zaki, M.D., Ph.D., Chief Medical Officer of ADC Therapeutics
Spruce Biosciences reported Q3 2026 financial results and confirmed it remains on track to submit a Biologics License Application (BLA) for TA-ERT in December 2026. The company also amended its loan agreement with Avenue Capital to increase tranche availability to $15 million and announced the separation of its CRHX-101 program into a new entity, Adrenyx Biosciences.
Term
Q3 2026
“We are executing with discipline as we complete the final steps toward our planned BLA submission for TA-ERT in December, which we believe will be a defining milestone for Spruce and for the children and families living with MPS IIIB.”
Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences
“Our amended Avenue Loan Agreement expands our near-term access to debt capital and extends our interest-only period, giving us added financial flexibility as we move through BLA review and prepare for a potential U.S. commercial launch.”
Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences
RB Global reported total revenue of $1.27 billion for the third quarter of 2026, a 17% increase compared to the same period in 2025, driven by growth in both service and inventory sales revenue. Net income available to common stockholders rose significantly to $128.7 million, or $0.70 per diluted share, up from $80.7 million in the prior year. The company also executed substantial common stock repurchases totaling $358.2 million during the quarter.
Whitehawk Therapeutics reported third quarter 2026 financial results, ending the period with $169.7 million in cash which is expected to fund operations into the second half of 2028. The company highlighted the initiation of its Phase 1 trial for HWK-206 and remains on track to report initial data from its HWK-007 and HWK-016 programs in the first half of 2027.
“We continue to dose escalate patients in our Phase 1 programs for HWK-007 and HWK-016 and remain on track to report initial data in the first half of 2027. We also initiated the Phase 1 trial of HWK-206, marking the advancement of all three of our original ADC programs into clinical development within the last 12 months.”
Dave Lennon, PhD, President and Chief Executive Officer
Orthofix Medical Inc. reported net sales of $207.9 million for the third quarter of 2026, a slight increase from $205.6 million in the prior year period. The company achieved a quarterly operating income of $1.5 million, a significant improvement from the $17.0 million operating loss in Q3 2025, though it still recorded a net loss of $6.1 million for the quarter.
Delcath Systems reported Q3 2026 total revenue of $35.1 million, a 70% increase year-over-year, driven by strong HEPZATO KIT sales in the U.S. The company achieved net income of $7.0 million and increased its full-year 2026 revenue guidance to a range of $115 million to $117 million.
Term
Q3 2026
“We are pleased with the continued momentum in our business, with meaningful progress across both commercial operations and clinical development. Growing physician experience with HEPZATO, strong engagement across our treatment center network, and increasing interest in its use alongside systemic therapies reinforce our confidence in the long-term opportunity.”
Gerard Michel, Chief Executive Officer of Delcath Systems
RB Global reported strong third quarter 2026 results with revenue increasing 17% year-over-year to $1.3 billion and net income rising 47% to $140.2 million. The company updated its full-year 2026 guidance, raising its GTV growth outlook to 14%-15% and narrowing its Adjusted EBITDA range to $1,525-$1,545 million. Additionally, the company declared a quarterly dividend of $0.33 per share and reported repurchasing $350 million of common stock during the quarter.
Term
Q3 2026
“Our third-quarter results demonstrate the strength of RB Global's marketplace and the consistent execution of our teams to deliver solid topline and bottom-line growth. We remain committed to gaining market share, delivering strong growth across all our businesses, and generating improved operating leverage.”
WhiteHorse Finance reported Q3 2026 financial results with total investment income of $14.8 million and core net investment income of $0.224 per share. The company's net asset value per share increased to $11.82, driven by favorable portfolio markups and a decline in non-accruals following a restructuring. Additionally, the board declared a quarterly distribution of $0.25 per share payable in January 2027.
Term
Q3 2026
“During the third quarter, we continued to execute on the priorities we have previously outlined, including actively managing restructured and underperforming credits and maintaining discipline in new originations. Net asset value per share increased for a second consecutive quarter, driven by favorable portfolio markups. Non-accruals declined following the completion of a restructuring, and there were no new additions to non-accrual during the quarter.”
Stuart Aronson, WhiteHorse Finance’s Chief Executive Officer
Turning Point Brands reported third-quarter 2026 financial results, highlighted by a 27% increase in consolidated net sales to $151.1 million, driven by 102.9% growth in its Modern Oral business. Despite the revenue growth, net income fell 81.4% to $3.9 million as the company significantly increased sales and marketing investments to expand distribution for its nicotine pouch brands. The company reaffirmed its full-year 2026 guidance for Modern Oral sales and EBITDA.
Term
Q3 2026
“I have been involved with Turning Point Brands for nearly 14 years and have never been more optimistic about its future. I am very excited to serve as CEO at such an important time. I have tremendous confidence in our team, our brands and our strategy.”
David Glazek, Chief Executive Officer
“We delivered another quarter of strong results, highlighted by continued growth in Modern Oral and progress across our heritage brands. Our investments in FRE and ALP are expanding distribution, strengthening consumer engagement and positioning us to become a leading player in the rapidly growing nicotine pouch category.”
Orthofix Medical reported Q3 2026 net sales of $207.9 million, a 1% increase over the prior year, and a net loss of $6.1 million. The company revised its full-year 2026 revenue guidance downward to $825M-$830M to reflect weaker performance in its U.S. Spine business and ongoing efforts to improve commercial execution.
Term
Q3 2026
“Continued growth in Limb Reconstruction and Therapeutic Solutions helped offset weaker Spine performance. In U.S. Spine, we are accelerating actions to strengthen commercial execution, improve instrument set supply and allocation, and increase asset productivity by focusing resources on our highest-performing distributor partners, products and market opportunities.”
Massimo Calafiore, President and Chief Executive Officer
Compass Therapeutics reported Q3 2026 financial results, ending the period with $163 million in cash and marketable securities, which is expected to fund operations into 2028. The company is currently preparing for a BLA submission for tovecimig in biliary tract cancer (BTC) and plans to engage the FDA regarding the necessity of additional survival studies.
Term
Q3 2026
“The third quarter was a period of sustained execution across our pipeline. We continue to prepare the BLA submission for tovecimig and are working to engage the FDA to bring this important therapy to patients with BTC as quickly as possible. The full COMPANION-002 results, now published in the Journal of Clinical Oncology and presented at ESMO, highlight the strength of the supportive data for tovecimig.”
Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors
“We are confident in the role tovecimig can play in the biliary tract cancer treatment landscape. We are committed to bringing tovecimig to patients as quickly as possible and the totality of the tovecimig data reinforces the urgency of our engagement with the FDA to define the most efficient path to a BLA submission.”
Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors
Motorcar Parts of America reported fiscal 2027 second quarter net sales of $169.2 million, a decline from $221.5 million in the prior year due to delayed customer orders and lower tariff pass-throughs. The company reported net income of $1.4 million and announced approximately $60 million in annualized new business awards expected to begin shipping by fiscal year-end. Due to the delayed orders and launches, the company issued revised guidance for the fiscal year.
CECO Environmental reported record third-quarter 2026 results, with revenue increasing 105% to $404.4 million and orders surging 234% to $777.6 million. The results represent the second quarter as a combined company following the acquisition of Thermon, contributing to a backlog of $2.19 billion. The company updated its 2026 outlook and introduced full-year 2027 guidance, citing strong visibility in its sales pipeline.
Term
Q3 2026
“Our strong third quarter results reflect CECO’s leadership in attractive and growing niche markets across a range of resilient industrial end markets. Customers around the world rely on our solutions and expertise to meet or exceed critical environmental and process safety requirements. Our sustainable growth is a testament to the strength of our incredible portfolio, the dedication of our employees, and the support of our global partners.”
Todd Gleason, CECO’s Chairman and Chief Executive Officer
“The continued visibility we have in our $2.2 billion backlog – the vast majority of which is permitted and underway, our rapidly growing $9 billion sales pipeline, and our productivity and synergy initiatives reinforce my confidence in our strategy and my conviction in our ability to deliver significant long-term value creation.”
Todd Gleason, CECO’s Chairman and Chief Executive Officer
ImmunityBio reported total assets of $609.4 million as of September 30, 2026, an increase from $501.9 million at year-end 2025, driven primarily by a rise in marketable securities. The company maintains a significant stockholders' deficit and continues to operate as a large accelerated filer following the commercial launch of its approved product, ANKTIVA.
Bicara Therapeutics reported Q3 2026 financial results, ending the period with $442.3 million in cash and marketable securities. The company achieved substantial enrollment in its FORTIFI-HN01 pivotal trial for head and neck cancer, with topline interim results expected in mid-2027. Management expects current cash reserves to fund operations into the first half of 2029.
Term
Q3 2026
“Ficerafusp alfa was purpose-built for HPV-negative head and neck cancer by inhibiting both EGFR and TGF-β, and the depth and durability of response it has demonstrated to date continue to set it apart in a disease with significant unmet need.”
Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer
“Achieving substantial enrollment in the FORTIFI-HN01 pivotal trial reflects strong execution by our team and growing recognition among investigators that HPV-negative disease requires a targeted approach grounded in its distinct biology.”
Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer
RadNet reported record third-quarter financial results for 2026, with total revenue increasing 22.1% year-over-year to $638.3 million. The company saw strong growth in advanced imaging volumes and its Digital Health segment, leading management to revise its full-year 2026 guidance ranges upward for revenue, Adjusted EBITDA, and free cash flow.
Term
Q3 2026
“We delivered record quarterly Revenue and Adjusted EBITDA (1) in the third quarter. Total Company Revenue grew 22.1% and Adjusted EBITDA (1) grew 23.8% compared with last year’s third quarter, and Adjusted EBITDA (1) margin expanded 23 basis points.”
Dr. Howard Berger, President and Chief Executive Officer of RadNet
“With strong performance across nearly every part of the core imaging center business, we are again raising certain guidance ranges in anticipation that full-year results will exceed both our original expectations and the revised ranges issued in conjunction with first and second quarter 2026 results.”
Dr. Howard Berger, President and Chief Executive Officer of RadNet
Air Industries Group reported significantly improved Q3 2026 financial results, with net sales increasing 41.1% to $14.6 million and net income reaching $0.9 million compared to a loss in the prior year. The company noted that results were impacted by $0.5 million in expenses related to its pending merger with Tenax Aerospace Acquisition, LLC.
Popular, Inc. updated its Q3 2026 financial results to recognize a $38 million additional provision for credit losses as a subsequent event. The adjustment stems from a quick service restaurant borrower filing for Chapter 11 bankruptcy, resulting in a decrease in previously reported net income and diluted EPS.
ImmunityBio reported Q3 2026 net product revenue of $48.7 million, a 53% increase year-over-year, driven by the adoption of ANKTIVA in the U.S. The company also highlighted a recent FDA label expansion for ANKTIVA and positive topline results from its QUILT-2.005 trial in BCG-naïve bladder cancer patients.
Roivant Sciences Ltd. reported 724,561,460 common shares outstanding as of November 3, 2026. The filing includes condensed consolidated financial statements for the three and six months ended September 30, 2026, and highlights risks related to biopharmaceutical product development, capital allocation, and its 'Vant' structure.
For the nine months ended September 30, 2026, AN2 Therapeutics reported a net loss of $26.2 million, a slight improvement from the $26.5 million loss in the prior year. Total assets increased to $82.0 million from $62.0 million at year-end 2025, primarily driven by an increase in short-term and long-term investments following a private placement of common stock.
Popular, Inc. reported a significant increase in debt securities available-for-sale, rising from $20.6 billion at year-end 2025 to $23.4 billion as of September 30, 2026. Conversely, debt securities held-to-maturity decreased from $7.3 billion to $5.5 billion during the same period. The company remains a large accelerated filer with over 62 million shares of common stock outstanding as of November 4, 2026.